Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Predictors of smoking severity in patients with schizophrenia and alcohol use disorders.

Meszaros ZS, Dimmock JA, Ploutz-Snyder RJ, Abdul-Malak Y, Leontieva L, Canfield K, Batki SL.

Am J Addict. 2011 Sep-Oct;20(5):462-7. doi: 10.1111/j.1521-0391.2011.00150.x. Epub 2011 Jul 18.

2.

Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics.

Scheller-Gilkey G, Woolwine BJ, Cooper I, Gay O, Moynes KA, Miller AH.

Am J Drug Alcohol Abuse. 2003 Aug;29(3):553-66.

PMID:
14510040
3.

Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.

Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB.

Arch Gen Psychiatry. 2006 Jun;63(6):622-9.

PMID:
16754835
4.

Item response analysis of the Positive and Negative Syndrome Scale.

Santor DA, Ascher-Svanum H, Lindenmayer JP, Obenchain RL.

BMC Psychiatry. 2007 Nov 15;7:66.

5.

Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.

Bobes J, Arango C, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group.

J Clin Psychiatry. 2010 Mar;71(3):280-6. doi: 10.4088/JCP.08m04250yel. Epub 2009 Nov 3. Erratum in: J Clin Psychiatry. 2011 Jul;72(7):1017.

PMID:
19895779
6.
7.

[Factors related to suicide attempts in a Tunisian sample of patients with schizophrenia].

Bouhlel S, M'solly M, Benhawala S, Jones Y, El-Hechmi Z.

Encephale. 2013 Feb;39(1):6-12. doi: 10.1016/j.encep.2012.06.003. Epub 2012 Sep 25. French.

PMID:
23095582
8.

Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.

Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH.

J Psychiatr Res. 2006 Oct;40(7):669-76. Epub 2006 Jun 9.

PMID:
16762371
9.

Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.

Emsley RA, Oosthuizen PP, Joubert AF, Roberts MC, Stein DJ.

J Clin Psychiatry. 1999 Nov;60(11):747-51.

PMID:
10584762
10.

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.

J Clin Psychiatry. 2002 Oct;63(10):931-5.

PMID:
12416603
11.

Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population.

Zhang XY, Chen DC, Tan YL, Xiu MH, Cui J, Hui L, Yang FD, Kosten TR.

Psychopharmacology (Berl). 2014 Jan;231(1):305-14. doi: 10.1007/s00213-013-3239-x. Epub 2013 Aug 21.

PMID:
23963531
12.

Smoking in schizophrenia: diagnostic specificity, symptom correlates, and illness severity.

Kotov R, Guey LT, Bromet EJ, Schwartz JE.

Schizophr Bull. 2010 Jan;36(1):173-81. doi: 10.1093/schbul/sbn066. Epub 2008 Jun 17.

13.

The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.

Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S.

J Clin Psychiatry. 2009 Jan;70(1):25-35. Epub 2008 Dec 2.

PMID:
19192472
14.

Predictors of switching antipsychotic medications in the treatment of schizophrenia.

Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ.

BMC Psychiatry. 2010 Sep 28;10:75. doi: 10.1186/1471-244X-10-75.

15.

Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences.

Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K.

Schizophr Res. 2004 Apr 1;67(2-3):157-66.

PMID:
14984874
16.

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA.

Arch Gen Psychiatry. 1999 Mar;56(3):241-7.

PMID:
10078501
17.

[Minor neurological and physical anomalies in patients with first-episode psychosis].

Mhalla A, Boussaïd N, Gassab L, Gaha L, Mechri A.

Encephale. 2013 Jun;39(3):149-54. doi: 10.1016/j.encep.2012.06.030. Epub 2012 Oct 12. French.

PMID:
23095597
18.

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A.

J Clin Psychiatry. 2003 Sep;64(9):998-1004.

PMID:
14628974
19.

The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.

Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS.

J Clin Psychiatry. 2013 Dec;74(12):1224-32. doi: 10.4088/JCP.12m08160.

PMID:
24434091
20.

Predictors of psychosis remission in psychotic disorders that co-occur with substance use.

Caton CL, Hasin DS, Shrout PE, Drake RE, Dominguez B, Samet S, Schanzer B.

Schizophr Bull. 2006 Oct;32(4):618-25. Epub 2006 Jul 27.

Items per page

Supplemental Content

Write to the Help Desk